Novo Nordisk's ADRs Slide After Eli Lilly Obesity Pill Results -- Market Talk

Dow Jones
04-17

1532 GMT - Novo Nordisk's American depositary receipts fall sharply after U.S. rival Eli Lilly said an experimental weight-loss pill met its goals in a pivotal study by helping diabetes patients lower blood sugar and even reduce weight. The Danish market is closed Thursday, but Novo Nordisk's ADRs--securities that are effectively a way for U.S. investors to buy stakes in foreign companies--drop 6.9% to $58.51, trading at levels last seen in late 2022, having lost nearly a third of their value since the start of the year. The results are pretty much a best-case scenario for Eli Lilly on weight loss, blood sugar control, tolerability and safety, analysts at Bank of America say in a research note. Eli Lilly shares jump 14%. (adria.calatayud@wsj.com)

 

(END) Dow Jones Newswires

April 17, 2025 11:32 ET (15:32 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10